Poly-L-glutamic acid (PGA) aided inhibitors of apoptotic protease activating factor 1 (Apaf-1): an antiapoptotic polymeric nanomedicine.
An antiapoptotic polymeric nanomedicine, PGA-peptoid 1, has been developed by the conjugation of a novel apoptotic protease activating factor 1 (Apaf-1) inhibitor (peptoid 1) to poly-L-glutamic acid (PGA). Full structural and biophysical characterization of the conjugate by different techniques has been accomplished. This macromolecule clearly enhances the antiapoptotic activity of peptoid 1 in different cell models.
Vicent
María J
MJ
Department of Medicinal Chemistry, Centro de Investigación Príncipe Felipe, Avenida Autopista del Saler, and Instituto de Biomedicina de Valencia, CSIC, E-46010 Valencia, Spain. mjvicent@cipf.es
Pérez-Payá
Enrique
E
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D053477:Apoptotic Protease-Activating Factor 1; D045744:Cell Line, Tumor; D003864:Depression, Chemical; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors*; D051379:Mice; D036103:Nanotechnology; D034444:Peptoids / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011099:Polyglutamic Acid / Q000737:chemistry*; D011506:Proteins / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
C506592:APAF1 protein, human; C506593:Apaf1 protein, mouse; D053477:Apoptotic Protease-Activating Factor 1; D047908:Intracellular Signaling Peptides and Proteins; D034444:Peptoids; D011506:Proteins; D011099:Polyglutamic Acid